Vertex Pharmaceuticals Incorporated

Research & Development
11010 Torreyana Road
San Diego
California
92121
United States

Tel: 858-404-6600
Fax: 858-404-6726

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.
Vertex Pharmaceuticals is an Equal Opportunity Employer.
Key Contacts Media: mediainfo@vrtx.com Investors: investorinfo@vrtx.com Patient Inquiries: clinical_trials@vrtx.com

This div will be replaced

179 articles about Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated Announces Webcast of its Presentation at the 2008 Morgan Stanley Global Healthcare Unplugged Conference

4/28/2008
Vertex Pharmaceuticals Incorporated Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients

4/24/2008
Vertex Pharmaceuticals Incorporated Announces Webcast of its Presentation at the Canaccord|Adams Hepatitis C Conference

4/8/2008
Vertex Pharmaceuticals Incorporated Announces the Date of its First Quarter 2008 Financial Results Conference Call and Webcast

4/7/2008
Vertex Pharmaceuticals Incorporated Announces Acceptance of Late-Breaker Abstract on Telaprevir, Investigational HCV Protease Inhibitor, for Presentation at EASL Annual Meeting

3/31/2008
Vertex Pharmaceuticals Incorporated Announces Positive Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis

3/27/2008
Vertex Pharmaceuticals Incorporated Announces Webcast of its Presentation at the Cowen and Company 28th Annual Health Care Conference

3/17/2008
Vertex Pharmaceuticals Incorporated Announces Pricing of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes

2/13/2008
Vertex Pharmaceuticals Incorporated Announces Webcast of its Presentation at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

2/1/2008
Vertex Pharmaceuticals Incorporated Announces the Date of its Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast

1/29/2008
Vertex Pharmaceuticals Incorporated to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor; Trial Timing Disappoints

1/24/2008
Vertex Pharmaceuticals Incorporated Reports Progress in Development of Investigational HCV Drug Telaprevir and Provides Business Update

1/7/2008
Vertex Pharmaceuticals Incorporated Announces Webcast of its Presentation at the 26th Annual JPMorgan Healthcare Conference

1/3/2008
Vertex Pharmaceuticals Incorporated Announces Webcasts of Its Presentations at Three Investor Conferences

11/6/2007
Vertex Pharmaceuticals Incorporated First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients

11/2/2007
Vertex Pharmaceuticals Incorporated Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update

10/30/2007
Vertex Pharmaceuticals Incorporated Announces the Date of its Third Quarter 2007 Financial Results Conference Call and Webcast

10/10/2007
Vertex Pharmaceuticals Incorporated Announces Publication of Abstracts for Presentation at 58th American Association for Study of Liver Diseases Meeting

10/1/2007
Vertex Pharmaceuticals Incorporated Announces Webcasts of its Presentations at Two Investor Conferences

9/17/2007

First
Previous
6
7
8
9
Last